This post was originally published on this site

At Spero we are privileged to be enrolling our pivotal study for SPR994, our oral antibiotic with the bacteria-killing power of an IV to treat patients with serious urinary tract infections.  A frightening sign of our deteriorating antibiotic arsenal is the three million patients in the US alone whose infections do not respond to oralRead More »

The post SPR994: A Long Shot, With Lots Of Twists And Turns To Phase III appeared first on Atlas Venture.